Can Nutritional Intervention Limit Protein Energy Wasting?

Raphael KL, Greene T, Beddhu S: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 81:300–306, 2012 16. Brymora A, Flisiński M, Johnson RJ, Goszka G, Stefańska A, Manitius J: Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transpl 27:608–612, 2012 17. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393, 2010 18. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease – what have we learned in 10 years? Semin Dial 23:498–509, 2010 19. Ridker PM, MacFadyen J, Cressman M, Glynn RJ: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Preventionan Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 55:1266–1273, 2010 20. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74:1461–1467, 2008 21. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395– 1407, 2009 22. Stenvinkel P, Andersson A, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O, Cederholm T: Do ACE-inhibitors suppress tumor necrosis factor-a production in advanced chronic renal failure? J Int Med 246:503–507, 1999 23. Yilmaz M, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P: Effect of renin angiotensin system blockade on pentraxin 3 levels in diabetic patients with proteinuria. Clin J Am Soc Nephrol 4:535–541, 2009 24. Yilmaz MI, Carrero JJ, Martı́n-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5:1174–1181, 2010 25. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E: Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 34:308–313, 2011 26. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD: Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353–361, 2010 27. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5:905–911, 2010 28. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249–255, 2008 29. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3:61–68, 2008 30. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al.: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7:934– 942, 2012 31. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA: The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 73:431–438, 2010 32. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526, 2007 33. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: IL-1b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 22:437–442, 2011 34. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium: Hingorani AD, Casas JP: The interleukin-6 receptor mendelian randomization analysis (IL6R MR) consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214–1224, 2012